A recent study has revealed alarming consequences of the US-UK pharmaceutical trade deal, predicting an excess of 229,000 deaths in the UK. This deal, which mandates increased spending on US medicines, diverts crucial funds from the NHS, exacerbating existing pressures on the healthcare system.
The agreement, signed in December, commits the UK to raise its spending on new US medicines significantly by 2036. While proponents argue it will enhance access to innovative treatments, the reality is that this financial commitment comes at a steep cost, impacting other vital areas of NHS funding.
Experts warn that the increased expenditure will lead to opportunity costs, meaning funds that could have been used for essential services like staffing and hospital care will be redirected. The study highlights that the most affected will be patients with cardiovascular, respiratory, gastrointestinal, and cancer conditions, who may face deteriorating health outcomes.
As the NHS grapples with these financial constraints, the implications for public health are dire. The potential for increased morbidity and mortality underscores the urgent need for a reevaluation of the deal’s terms to safeguard the health of the UK population.
Source: Al Jazeera
